| Literature DB >> 35308746 |
Mansur Assaad1, Anam Aqeel2, James Walsh1.
Abstract
Follicular bronchiolitis (FB) associated with immunodeficiency is not commonly reported in peer-reviewed literature. Herein, we present a case of FB associated with IgG2/IgG4 deficiency. The presence of non-specific respiratory symptoms, including cough and dyspnea with exertion, led to a CT scan of the chest, which showed diffuse, peripheral, micronodular tree-in-bud opacities and an isolated area of bronchiectasis. Despite an extensive workup, including a non-diagnostic transbronchial biopsy, no obvious etiology for the patient's clinical presentation was established, and a surgical lung biopsy was needed to confirm the diagnosis of FB. Further lab testing to evaluate for immunodeficiency confirmed an isolated deficiency in both IgG2 and IgG4. Although treating the underlying cause of FB is the standard of care, there are no established guidelines regarding standard management of FB associated with immunodeficiency, specifically IgG2/IgG4 deficiency. Therefore, a careful evaluation for immunodeficiency should be considered when evaluating for the underlying etiology of FB, as management options differ depending on the underlying diagnosis.Entities:
Keywords: follicular bronchiolitis; igg2/igg4 deficiency; immunodeficiency; interstitial lung disease; tree-in-bud
Year: 2022 PMID: 35308746 PMCID: PMC8923243 DOI: 10.7759/cureus.22183
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Axial CT image showing multiple bilateral centrilobular and tree-in-bud nodules, concerning for small airway disease.
Figure 2Hematoxylin and eosin (H&E) stain from surgical lung biopsy showing airway narrowing with enlarged peribronchiolar lymphoid follicles, consistent with follicular bronchiolitis.
Pulmonary function tests before and after treatment.
FEV1, forced expiratory volume at one second; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity of the lung for carbon monoxide; N/A, not applicable.
| Lower limit of normal | Initial | Two months after starting treatment | |
| FEV1 (L) | 2.63 | 1.81 | 2.50 |
| FVC (L) | 3.26 | 2.23 | 3.14 |
| FEV1/FVC (%) | 73 | 66 | 80 |
| TLC (L) | 4.38 | 4.25 | N/A |
| DLCO (mL/min/mmHg) | 18.46 | 15.98 | 22.63 |